- ¥4bn
- ¥4bn
- ¥11bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.65 | ||
| Price to Tang. Book | 0.72 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.3 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.2% | ||
| Return on Equity | -10.1% | ||
| Operating Margin | -5.41% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 8,674.5 | 11,046.68 | 11,046.14 | 12,576.57 | 11,429.68 | n/a | n/a | 25.98% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +295.15 | n/a | n/a | +70.07 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TRANS GENIC INC. is a Japan-based company mainly engaged in the biotechnology business. The Company has three business segments. The Contract Research Organization (CRO) segment is engaged in the provision of contract clinical tests for pharmaceuticals and foods, pharmacodynamic pharmacology tests, safety pharmacology tests, pharmacokinetic tests, and non-clinical tests such as safety tests for pesticides and food, the contract production of genetically modified mice and antibody, the sale of model mice, as well as the development of new biomarkers. The Diagnostic Analysis segment is engaged in the provision of pathological diagnosis services, gene analysis contract services, and drug discovery support services for individualized medicine. The TGBS segment is engaged in the provision of advice and support services for business succession and revitalization in various fields, as well as the electronic commerce (EC) business such as the retail and wholesale of electrical products.
Directors
- Kenji Fukunaga PRE (51)
- Kenichi Yamamura CTO (64)
- Tamami Sakamoto DRC (49)
- Yutaka Funabashi DRC (39)
- Tsutomu Seito IND (70)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 21st, 1998
- Public Since
- December 10th, 2002
- No. of Shareholders
- 12,707
- No. of Employees
- 236
- Sector
- Diversified Retail
- Industry
- Consumer Cyclicals
- Exchange
Tokyo Stock Exchange- Shares in Issue
- 16,688,819
- Address
- ibbFUKUOKA Bldg., FUKUOKA-SHI, 810-0001
- Web
- http://www.transgenic.co.jp/
- Phone
- +81 922888470
- Auditors
- Deloitte Touche Tohmatsu LLC
Upcoming Events for 2342
Similar to 2342
Aeon Hokkaido
Tokyo Stock Exchange
Aeon Kyushu Co
Tokyo Stock Exchange
ANAP
Tokyo Stock Exchange
Beenos
Tokyo Stock Exchange
Belluna Co
Tokyo Stock Exchange
FAQ
What is the Trans Genic share price?
As of Today at 19:22 UTC, shares in Trans Genic are trading at ¥229. This share price information is delayed by 15 minutes.
How has the Trans Genic share price performed this year?
Shares in Trans Genic last closed at ¥229 and the price had moved by -28.44% over the past 365 days. In terms of relative price strength the Trans Genic share price has underperformed the Nikkei 225 Index by -48.91% over the past year.
What are the analyst and broker recommendations for Trans Genic?
There is no consensus recommendation for this security.
What is the Trans Genic dividend yield?
The Trans Genic dividend yield is 1.31% based on the trailing twelve month period.
Does Trans Genic pay a dividend?
Last year, Trans Genic paid a total dividend of ¥3, and it currently has a trailing dividend yield of 1.31%.Looking ahead, the next dividend pay date is 2024-06-01.
When does Trans Genic next pay dividends?
We do not have data on when Trans Genic is to next pay dividends. The historic dividend yield on Trans Genic shares is currently 1.31%.
How do I buy Trans Genic shares?
To buy shares in Trans Genic you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Trans Genic?
As of the previous close price of ¥229, shares in Trans Genic had a market capitalisation of ¥4bn.
Where are Trans Genic shares listed?
Here are the trading details for Trans Genic:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 2342
What kind of share is Trans Genic?
Based on an overall assessment of its quality, value and momentum Trans Genic is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Trans Genic share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Trans Genic share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Trans Genic. Over the past six months, its share price has underperformed the Nikkei 225 Index by -33.4%.
As of the last closing price of ¥229, shares in Trans Genic were trading -15.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Trans Genic PE Ratio?
The Trans Genic PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥229.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Trans Genic?
Trans Genic's management team is headed by:
- Kenji Fukunaga - PRE
- Kenichi Yamamura - CTO
- Tamami Sakamoto - DRC
- Yutaka Funabashi - DRC
- Tsutomu Seito - IND